planning program

Cancer and Cancer Survivorship Program

A research and patient-participation program for adults with active cancer, cancer survivors, and people experiencing persistent fatigue or functional limitations related to cancer or its treatment.

This program is being prepared. You can join the interest list now, complete available steps, and receive updates as more activities open. Recruitment has not begun; you may register interest while IRB and activation requirements are completed. Private health details stay in Mito Map.

Credit schedule pending governance approval

Current funded and qualifying value: $0. Future value is undetermined.
Register interestCompare all programs

Planning terms may change. MDA may revise program goals, participant targets, credit amounts, credit maximums, eligible activities, timelines, and related rules as research needs, funding, operations, governance review, applicable law, or other program needs evolve. Displayed figures are current planning terms, not permanent commitments or guaranteed benefits.

Why join

Help shape a study-ready program.

Help researchers understand how cancer, treatment, recovery, and survivorship affect energy and physical function over time. Approved group-level findings may support future studies, supportive-care research, and therapy development. Participation does not provide cancer treatment or replace oncology care.

Who this program is for

  • Adults receiving treatment for cancer when remote functional testing is considered appropriate
  • Adults living with active cancer
  • Cancer survivors
  • Adults with persistent treatment-related fatigue or reduced function
  • People who meet study safety screening requirements

Study plan

Initial research questions

  • Does the Energy Score track independently measured functional changes during treatment or survivorship?
  • How do treatment phase, time since treatment, and recent treatment changes affect energy and function?
  • How do anemia, pain, cachexia, sleep disruption, acute illness, and medication changes affect study measurements?
  • Are remote functional assessments feasible and safe for this population?

Study-aligned measurements

  • Canonical Mito Map Energy Score
  • Grip strength and five-times sit-to-stand, with approved alternatives
  • Cancer status and treatment phase
  • Time since treatment and recent treatment changes
  • Fatigue, pain, sleep, acute illness, anemia, and cachexia when known
  • Function, assessment burden, measurement failures, and adverse events

Planning and safeguards

Not recruiting until required review and activation are complete.

Initial planned participants
50

Study-aligned enrollment goal

Minimum analyzable participants
40

Initial analysis goal

Current enrollment
0

Planning stage

Current funded balance
$0

Future value is undetermined

Data handling: Approved summaries and aggregate information only; detailed records remain in Mito Map.

Important limitation: MDA and Mito Map do not diagnose or treat cancer. Participation must not delay or change oncology care. Research scores are not measures of treatment effectiveness, cancer progression, or prognosis.

Credit disclosure: Credits record verified participation activity. They are not cash, equity, tokens, ownership, royalties, or guaranteed payments. Credits may be worth $0. Any future eligibility or value may depend on approved uses of combined participant data, available qualifying value, applicable law, and the program rules in effect at that time. Development of a drug, therapy, diagnostic, or other product does not guarantee a distribution to participants.

Researcher program

Researchers who publish with Alliance data can share in the value they help create.

When a researcher uses consented Alliance data, publishes useful findings, and follows the program's data-use and publication rules, their work can be recognized through a separate Researcher Value Pool.

Researcher value awards are not guaranteed. Eligibility depends on publication status, data-use compliance, program approval, available qualifying value, and applicable law.

Researcher pool stage
pre-revenue

Separate from the patient pool

Researcher goal
$22,500,000

20% of the combined program goal

Strategic researcher range
$8,875,000-$15,500,000

Planning range for future qualifying value

Program share
20%

Share of combined patient and researcher program goals

Current balance
$0

Current funded balance

Qualifying research impact value
$0

Tracked for this program

Program
Cancer and Cancer Survivorship Program

Possible future payments

Credits do not guarantee payment.

This program is currently at the pre-revenue stage. Its patient pool currently holds $0. It has recorded $0 in qualifying revenue and $0 in approved past distributions.

If the program receives qualifying money and approves a Patient Success Distribution, members generally need active enrollment and at least 50 qualifying credits to be considered. Any approved amount would depend on the program rules and each eligible member's credits. Payment is never guaranteed.